See more : AAK AB (publ.) (ARHUF) Income Statement Analysis – Financial Results
Complete financial analysis of LifeMD, Inc. (LFMDP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of LifeMD, Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Proton Motor Power Systems PLC (P6K0.DE) Income Statement Analysis – Financial Results
- Teyi Pharmaceutical Group Co.,Ltd (002728.SZ) Income Statement Analysis – Financial Results
- Wellbeing Digital Sciences Inc. (KONEF) Income Statement Analysis – Financial Results
- The South Indian Bank Limited (SOUTHBANK.NS) Income Statement Analysis – Financial Results
- Autoco.com, Inc. (AOOO) Income Statement Analysis – Financial Results
LifeMD, Inc. (LFMDP)
About LifeMD, Inc.
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a telehealth platform brand that offers access to virtual medical treatment, prescription medications, patented-doctor formulated OTC products, and an FDA approved medical device for male and female hair loss, and female specific topical compounded medications for hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; LifeMD Primary Care, a personalized subscription-based virtual primary care platform that provides patients with primary care, urgent care, and chronic care needs, as well as .offers a mobile first platform that incorporates virtual consultations and treatment, prescription medications, diagnostics, and imaging; Cleared, a telehealth brand that provides personalized treatments for allergy, asthma, and immunology; and Nava MD, a female-oriented tele-dermatology and skincare brand that offers virtual medical treatment from dermatologists and other providers. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. LifeMD sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 152.55M | 119.03M | 92.88M | 37.29M | 12.47M | 8.32M | 5.05M | 5.24M | 1.22M | 714.16K | 808.36K | 673.78K | 743.83K |
Cost of Revenue | 18.90M | 18.67M | 18.00M | 8.91M | 3.27M | 1.97M | 1.48M | 1.95M | 247.77K | 172.85K | 181.30K | 125.62K | 241.26K |
Gross Profit | 133.65M | 100.37M | 74.88M | 28.39M | 9.20M | 6.36M | 3.57M | 3.29M | 971.09K | 541.31K | 627.06K | 548.16K | 502.56K |
Gross Profit Ratio | 87.61% | 84.32% | 80.62% | 76.12% | 73.77% | 76.35% | 70.65% | 62.85% | 79.67% | 75.80% | 77.57% | 81.36% | 67.56% |
Research & Development | 6.06M | 2.97M | 778.77K | 446.75K | 222.88K | 120.54K | 0.00 | 0.00 | 23.93K | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 51.69M | 46.96M | 39.57M | 42.21M | 2.40M | 3.33M | 2.98M | 2.76M | 978.72K | 1.07M | 1.17M | 1.09M | 1.08M |
Selling & Marketing | 76.45M | 78.37M | 82.54M | 41.67M | 8.17M | 5.08M | 1.66M | 1.71M | 230.66K | 57.25K | 0.00 | 0.00 | 0.00 |
SG&A | 128.15M | 125.33M | 122.11M | 83.88M | 10.57M | 8.41M | 4.64M | 4.47M | 1.21M | 1.07M | 1.17M | 1.09M | 1.08M |
Other Expenses | 13.93M | 11.75M | 6.29M | 1.88M | 1.30M | -516.98K | 215.13K | 0.00 | 0.00 | 57.88K | 54.33K | 80.55K | 77.50K |
Operating Expenses | 148.46M | 140.05M | 129.18M | 86.21M | 12.09M | 8.41M | 4.64M | 4.47M | 1.23M | 1.07M | 1.17M | 1.09M | 1.08M |
Cost & Expenses | 167.04M | 158.72M | 147.18M | 95.11M | 15.36M | 10.38M | 6.12M | 6.41M | 1.48M | 1.25M | 1.35M | 1.21M | 1.32M |
Interest Income | 0.00 | 1.28M | 3.02M | 1.67M | 761.15K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 2.60M | 1.28M | 3.02M | 1.67M | 761.15K | 354.39K | 100.52K | 48.61K | 37.48K | 4.68K | 3.39K | 3.37K | 21.26K |
Depreciation & Amortization | 6.60M | 3.77M | 868.76K | 397.77K | 335.61K | 195.78K | 1.23M | 43.75K | 43.75K | 56.98K | 56.97K | 56.97K | 56.69K |
EBITDA | -8.21M | -39.61M | -53.95M | -57.48M | -2.55M | -1.86M | -138.43K | -1.17M | -91.21K | -416.02K | -225.10K | -402.50K | -442.18K |
EBITDA Ratio | -5.38% | -27.07% | -53.23% | -155.04% | -20.48% | -11.23% | -21.12% | -22.42% | -17.92% | -66.36% | -60.55% | -71.69% | -69.87% |
Operating Income | -14.49M | -39.69M | -54.30M | -57.82M | -2.89M | -2.06M | -1.07M | -1.17M | -262.22K | -530.88K | -546.41K | -540.03K | -576.37K |
Operating Income Ratio | -9.50% | -33.34% | -58.47% | -155.04% | -23.18% | -24.70% | -21.12% | -22.42% | -21.51% | -74.34% | -67.59% | -80.15% | -77.49% |
Total Other Income/Expenses | -2.92M | -4.97M | -7.02M | -2.58M | -761.15K | -354.39K | -150.92K | -48.61K | 89.79K | 53.19K | 260.95K | 77.18K | 56.24K |
Income Before Tax | -17.41M | -44.66M | -61.32M | -60.40M | -3.65M | -1.48M | -1.22M | -1.22M | -172.43K | -477.69K | -285.46K | -462.85K | -520.13K |
Income Before Tax Ratio | -11.41% | -37.52% | -66.02% | -161.96% | -29.28% | -17.84% | -24.11% | -23.35% | -14.15% | -66.89% | -35.31% | -68.69% | -69.93% |
Income Tax Expense | 428.00K | 360.70K | 7.70K | 122.50K | -122.50K | -124.70K | -12.49K | -115.75K | -13.20K | -17.20K | -17.20K | -17.20K | -17.20K |
Net Income | -20.60M | -45.02M | -61.32M | -60.52M | -3.53M | -1.24M | -1.21M | -1.11M | -61.99K | -460.49K | -268.26K | -445.65K | -502.93K |
Net Income Ratio | -13.50% | -37.82% | -66.03% | -162.29% | -28.30% | -14.91% | -23.86% | -21.14% | -5.09% | -64.48% | -33.19% | -66.14% | -67.61% |
EPS | -0.70 | -1.45 | -2.27 | -4.24 | -0.36 | -0.14 | -0.14 | -0.16 | -0.01 | -0.08 | -0.05 | -0.08 | -0.07 |
EPS Diluted | -0.70 | -1.45 | -2.27 | -4.24 | -0.36 | -0.14 | -0.14 | -0.16 | -0.01 | -0.07 | -0.04 | -0.08 | -0.07 |
Weighted Avg Shares Out | 33.91M | 30.98M | 27.01M | 14.28M | 9.90M | 8.84M | 8.80M | 7.05M | 6.16M | 6.07M | 5.88M | 5.50M | 7.52M |
Weighted Avg Shares Out (Dil) | 33.91M | 30.98M | 27.01M | 14.28M | 9.90M | 9.05M | 8.80M | 7.05M | 6.40M | 6.15M | 6.02M | 5.78M | 7.52M |
LifeMD Appoints Dr. Calum MacRae to its Board of Directors
LifeMD to Report First Quarter 2024 Financial Results on May 8
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
LifeMD to Participate in the 23rd Annual Needham Virtual Healthcare Conference
LifeMD, Inc. (LFMD) Q4 2023 Earnings Call Transcript
LifeMD Reports Fourth Quarter 2023 Results
LifeMD to Participate in the 11th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
LifeMD to Participate in the Maxim Group 2024 Healthcare IT Virtual Conference
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
LifeMD and Medifast Partner to Offer Transformative Weight Management Solution
Source: https://incomestatements.info
Category: Stock Reports